Crescent Biopharma, Inc. (CBIO) stock
CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.04−0.46 (-3.41%)
Close on Nov 17, 2026Market cap $484.36MP/E –Yield –
Crescent Biopharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Crescent Biopharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$72.68M. For fiscal 2025 it was -$71.53M. The highest annual figure on record is -$4.28M in fiscal 2014.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$71.53M | – |
| FY2024 | Dec 31, 2024 | -$31.10M | – |
| FY2023 | Dec 31, 2023 | -$34.88M | – |
| FY2022 | Dec 31, 2022 | -$46.46M | – |
| FY2021 | Dec 31, 2021 | -$57.49M | – |
| FY2020 | Dec 31, 2020 | -$39.24M | – |
| FY2019 | Dec 31, 2019 | -$51.98M | – |
| FY2018 | Dec 31, 2018 | -$43.33M | – |
| FY2017 | Dec 31, 2017 | -$29.77M | – |
| FY2016 | Dec 31, 2016 | -$29.73M | – |
| FY2015 | Dec 31, 2015 | -$8.24M | – |
| FY2014 | Dec 31, 2014 | -$4.28M | – |
| FY2013 | Dec 31, 2013 | -$15.54M | – |
| FY2012 | Dec 31, 2012 | -$10.47M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.46M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.94M | – |
| Q4 FY2025 | Dec 31, 2025 | -$26.74M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.54M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.40M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.85M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.70M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.99M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.89M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.51M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.61M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.68M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.97M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.61M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.91M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.23M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.70M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.81M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.95M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.61M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.13M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.69M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.50M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.55M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.50M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.79M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.45M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.39M | – |
| Q1 FY2019 | Mar 31, 2019 | -$14.35M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.98M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.08M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.06M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.21M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.37M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.23M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.11M | – |
| Q1 FY2017 | Mar 31, 2017 | -$9.06M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.95M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.47M | – |
See a number that looks wrong?